Genolimzumab

Drug Profile

Genolimzumab

Alternative Names: CBT 501; GB 226; PD-1 antibody - Genor Biopharma

Latest Information Update: 29 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CBT Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Immunostimulants; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Mar 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (IV) (NCT03053466)
  • 23 Feb 2017 Pharmacodynamics data from the preclinical studies released by CBT Pharmaceuticals
  • 21 Feb 2017 CBT Pharmaceuticals plans a phase I trial for Solid tumours (Advanced or Relapsed/Recurrent) in Australia (NCT03053466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top